Abstract
Background. When classical Kaposi's sarcoma (CKS) shows an aggressive behaviour, the use of systemic chemotherapy is indicated. Several drugs are active in this disease, but the role of single agents, both in the first and second line, is not yet clear. The 20 years experience of a referral group in Italy is reported here. Methods. One hundred and twenty patients were treated with seven drugs in monochemotherapy: vinblastine, vinorelbine and oral etoposide in the first line and vinblastine, i.v. etoposide, gemcitabine and i.m. bleomycin in the second line. Objective responses and toxicity were evaluated according to WHO criteria. Results. In the first line, the activity of therapy was similar (CR+ PR: 60-80%), whereas in the second line it was 50% for drugs used in the second line apart from gemcitabine which has given 100% response. Toxicity was limited and acceptable for each treatment. Personal experience confirms the usefulness of treating patients affected by aggressive CKS with systemic chemotherapy, in order to obtain control of the disease and to reduce the related symptoms. Conclusions. The evaluation of the role of a drug in comparison to another one requires the implementation of a large comparative trials, in order to establish a 'standard' systemic treatment for this disease.
| Original language | Italian |
|---|---|
| Pages (from-to) | 433-437 |
| Number of pages | 5 |
| Journal | Giornale Italiano di Dermatologia e Venereologia |
| Volume | 135 |
| Issue number | 4 |
| Publication status | Published - 2000 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
Cite this
Chemioterapia nel sarcoma di Kaposi mediterraneo : 20 anni di esperienza. / Brambilla, L.; Labianca, R.; Fossati, S.; Ferrucci, S.; Taglioni, M.; Boneschi, V.
In: Giornale Italiano di Dermatologia e Venereologia, Vol. 135, No. 4, 2000, p. 433-437.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Chemioterapia nel sarcoma di Kaposi mediterraneo
T2 - 20 anni di esperienza
AU - Brambilla, L.
AU - Labianca, R.
AU - Fossati, S.
AU - Ferrucci, S.
AU - Taglioni, M.
AU - Boneschi, V.
PY - 2000
Y1 - 2000
N2 - Background. When classical Kaposi's sarcoma (CKS) shows an aggressive behaviour, the use of systemic chemotherapy is indicated. Several drugs are active in this disease, but the role of single agents, both in the first and second line, is not yet clear. The 20 years experience of a referral group in Italy is reported here. Methods. One hundred and twenty patients were treated with seven drugs in monochemotherapy: vinblastine, vinorelbine and oral etoposide in the first line and vinblastine, i.v. etoposide, gemcitabine and i.m. bleomycin in the second line. Objective responses and toxicity were evaluated according to WHO criteria. Results. In the first line, the activity of therapy was similar (CR+ PR: 60-80%), whereas in the second line it was 50% for drugs used in the second line apart from gemcitabine which has given 100% response. Toxicity was limited and acceptable for each treatment. Personal experience confirms the usefulness of treating patients affected by aggressive CKS with systemic chemotherapy, in order to obtain control of the disease and to reduce the related symptoms. Conclusions. The evaluation of the role of a drug in comparison to another one requires the implementation of a large comparative trials, in order to establish a 'standard' systemic treatment for this disease.
AB - Background. When classical Kaposi's sarcoma (CKS) shows an aggressive behaviour, the use of systemic chemotherapy is indicated. Several drugs are active in this disease, but the role of single agents, both in the first and second line, is not yet clear. The 20 years experience of a referral group in Italy is reported here. Methods. One hundred and twenty patients were treated with seven drugs in monochemotherapy: vinblastine, vinorelbine and oral etoposide in the first line and vinblastine, i.v. etoposide, gemcitabine and i.m. bleomycin in the second line. Objective responses and toxicity were evaluated according to WHO criteria. Results. In the first line, the activity of therapy was similar (CR+ PR: 60-80%), whereas in the second line it was 50% for drugs used in the second line apart from gemcitabine which has given 100% response. Toxicity was limited and acceptable for each treatment. Personal experience confirms the usefulness of treating patients affected by aggressive CKS with systemic chemotherapy, in order to obtain control of the disease and to reduce the related symptoms. Conclusions. The evaluation of the role of a drug in comparison to another one requires the implementation of a large comparative trials, in order to establish a 'standard' systemic treatment for this disease.
KW - Aged
KW - Antineoplastic agents
KW - Combined
KW - Drug therapy
KW - Kaposi
KW - Sarcoma
KW - Therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=0033800374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033800374&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:0033800374
VL - 135
SP - 433
EP - 437
JO - Minerva dermatologica
JF - Minerva dermatologica
SN - 0392-0488
IS - 4
ER -